Skip to main content
UploadLanguage (EN)Support
BusinessMobileSocial MediaMarketingTechnologyArt & PhotosCareerDesignEducationPresentations & Public SpeakingGovernment & NonprofitHealthcareInternetLawLeadership & ManagementAutomotiveEngineeringSoftwareRecruiting & HRRetailSalesServicesScienceSmall Business & EntrepreneurshipFoodEnvironmentEconomy & FinanceData & AnalyticsInvestor RelationsSportsSpiritualNews & PoliticsTravelSelf ImprovementReal EstateEntertainment & HumorHealth & MedicineDevices & HardwareLifestyle
AU
Uploaded byAshish Umale
161 views

Comprehensive Pharmacology of Anti-Hyperlipidemic Drugs for Cardiovascular Health

Detailed overview of anti-hyperlipidemic drugs, their mechanisms, therapeutic uses, adverse effects, and clinical applications in managing hyperlipidemia and preventing cardiovascular diseases.

Healthcare◦
Related topics:
B-Pharmacy• D-Pharm•
PREPARED BY Prof. ASHISH N. UMALE M. PHARM IN PHARMACOLOGY ASSISTANT PROFESSOR SHRADDHA INSTITUTE OF PHARMACY, WASHIM- 444505 PHARMACOLOGY-II
PHARMACOLOGY OF DRUGS ACTING ON THE CARDIOVASCULAR SYSTEM ANTI-HYPERLIPIDEMIC DRUGS (LIPID-LOWERING DRUGS) •INTRODUCTION •Hyperlipidemia is a metabolic disorder characterized by elevated levels of plasma lipids such as total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), or reduced levels of high-density lipoprotein cholesterol (HDL-C). •Elevated LDL cholesterol is a major risk factor for atherosclerosis, coronary artery disease (CAD), stroke, and peripheral vascular disease. •Anti-hyperlipidemic drugs are medications that lower plasma lipid levels by reducing cholesterol synthesis, decreasing intestinal cholesterol absorption, increasing LDL receptor expression, promoting cholesterol excretion, or enhancing lipoprotein metabolism. •These drugs reduce cardiovascular morbidity and mortality by preventing the progression of atherosclerosis
CLASSIFICATION OF ANTI-HYPERLIPIDEMIC DRUGS Class Drugs HMG-CoA Reductase Inhibitors (Statins) Atorvastatin, Rosuvastatin, Simvastatin, Lovastatin, Pitavastatin Fibric Acid Derivatives (Fibrates) Fenofibrate, Gemfibrozil, Bezafibrate Bile Acid Sequestrants Cholestyramine, Colestipol, Colesevelam Cholesterol Absorption Inhibitor Ezetimibe Nicotinic Acid (Niacin) Nicotinic acid PCSK9 Inhibitors Alirocumab, Evolocumab ATP Citrate Lyase Inhibitor Bempedoic acid
•PATHOPHYSIOLOGY OF HYPERLIPIDEMIA Genetic Factors / High-fat Diet / Diabetes / Obesity / Sedentary Lifestyle ↓ Increased Hepatic Cholesterol & Triglyceride Synthesis ↓ Increased VLDL Production by Liver ↓ Increased LDL Cholesterol in Blood ↓ LDL Penetrates Vascular Endothelium ↓ Oxidation of LDL by Free Radicals ↓ Macrophages Engulf Oxidized LDL ↓ Foam Cell Formation ↓ Fatty Streak Formation ↓ Atherosclerotic Plaque Formation ↓ Narrowing of Coronary & Peripheral Arteries ↓ Reduced Blood Flow to Vital Organs ↓ Angina • Myocardial Infarction • Stroke • Peripheral Artery Disease
1. HMG-CoA REDUCTASE INHIBITORS (STATINS) Examples:- Atorvastatin, Rosuvastatin, Simvastatin, Lovastatin, Fluvastatin Pitavastatin Mechanism of Action Statin Administration ↓ Inhibition of HMG-CoA Reductase ↓ ↓ Hepatic Cholesterol Synthesis ↓ ↓ Intracellular Cholesterol ↓ Upregulation of Hepatic LDL Receptors ↓ ↑ Uptake of LDL from Blood ↓ ↓ Plasma LDL Cholesterol ↓ Reduced Atherosclerosis ↓ Prevention of Cardiovascular Disease
•Therapeutic Effects •Markedly lowers LDL cholesterol (20–60%). •Moderately lowers triglycerides. •Slightly increases HDL cholesterol. •Stabilizes atherosclerotic plaques. •Reduces vascular inflammation. •Decreases cardiovascular mortality. •Clinical Uses •Primary hypercholesterolemia. •Mixed dyslipidemia. •Familial hypercholesterolemia. •Prevention of myocardial infarction. •Stroke prevention. •Peripheral arterial disease. •Adverse Effects •Myalgia. •Myopathy. •Elevated liver enzymes. •Hepatitis. •Gastrointestinal upset. •Mild increase in blood glucose. •Contraindications •Active liver disease. •Pregnancy. •Lactation. •Severe hepatic dysfunction. •Previous statin-induced myopathy.
2. FIBRIC ACID DERIVATIVES (FIBRATES) Example:- Fenofibrate, Gemfibrozil, Bezafibrate Mechanism of Action Fibrate Administration ↓ Activation of PPAR-α ↓ ↑ Lipoprotein Lipase Activity ↓ ↑ Breakdown of VLDL & Triglycerides ↓ ↓ Plasma Triglycerides ↓ ↑ HDL Cholesterol ↓ Reduced Risk of Pancreatitis & Cardiovascular Disease
•Therapeutic Effects •Markedly lowers triglycerides. •Moderately increases HDL. •Slightly lowers LDL. •Clinical Uses •Hypertriglyceridemia. •Mixed dyslipidemia. •Prevention of pancreatitis due to severe hypertriglyceridemia. •Adverse Effects •Dyspepsia. •Gallstones. •Myopathy •Elevated liver enzymes. •Contraindications •Gallbladder disease. •Severe liver disease. •Severe renal impairment. •Pregnancy.
3. BILE ACID SEQUESTRANTS Examples:- Cholestyramine, Colestipol, Colesevelam Mechanism of Action Drug Administration ↓ Binding of Bile Acids in Intestine ↓ Increased Fecal Excretion ↓ ↓ Hepatic Cholesterol ↓ ↑ LDL Receptor Expression ↓ ↑ LDL Clearance ↓ ↓ Plasma LDL Cholesterol
•Therapeutic Effects •Reduces LDL cholesterol. •Slight increase in HDL. •Clinical Uses •Primary hypercholesterolemia. •Combination therapy with statins. •Pruritus due to bile acid accumulation. •Adverse Effects •Constipation. •Bloating. •Flatulence. •Drug interactions. •Contraindications •Complete biliary obstruction. Severe hypertriglyceridemia.
4. Cholesterol Absorption Inhibitor Example:- Ezetimibe Mechanism of Action Ezetimibe Administration ↓ Blocks NPC1L1 Transporter ↓ ↓ Cholesterol Absorption ↓ ↓ Hepatic Cholesterol ↓ ↑ LDL Receptors ↓ ↑ LDL Clearance ↓ ↓ LDL Cholesterol
•Therapeutic Effects •Reduces LDL by approximately 18–25%. •Additive effect with statins. •Clinical Uses •Primary hypercholesterolemia. •Familial hypercholesterolemia. •Statin intolerance. •Adverse Effects •Headache. •Diarrhea. •Elevated liver enzymes •Contraindications •Severe hepatic disease. Pregnancy
5. NICOTINIC ACID (NIACIN) Mechanism of Action Niacin Administration ↓ ↓ Lipolysis in Adipose Tissue ↓ ↓ Free Fatty Acids to Liver ↓ ↓ VLDL Synthesis ↓ ↓ LDL Cholesterol ↓ ↑ HDL Cholesterol
•Therapeutic Effects •Decreases LDL. •Decreases triglycerides. •Produces the greatest increase in HDL. •Clinical Uses •Mixed dyslipidemia. •Hypertriglyceridemia •Adverse Effects •Flushing. •Hyperuricemia. •Hyperglycemia. •Hepatotoxicity. •Pruritus. •Contraindications •Liver disease. •Active peptic ulcer. •Severe gout. •Poorly controlled diabetes.
6. PCSK9 INHIBITORS Examples:- Alirocumab, Evolocumab Mechanism of Action PCSK9 Inhibitor ↓ Blocks PCSK9 Protein ↓ Prevents LDL Receptor Degradation ↓ ↑ LDL Receptors ↓ ↑ LDL Uptake ↓ ↓ Plasma LDL Cholesterol
•Therapeutic Effects •Reduces LDL by 50–70%. •Slows progression of atherosclerosis. •Reduces cardiovascular events. •Clinical Uses •Familial hypercholesterolemia. •Patients not controlled with statins. •Statin intolerance. •Adverse Effects •Injection-site reactions. •Nasopharyngitis. •Flu-like symptoms. •Contraindications •Hypersensitivity to monoclonal antibodies.
7. BEMPEDOIC ACID Mechanism of Action Bempedoic Acid ↓ ATP Citrate Lyase Inhibition ↓ ↓ Cholesterol Synthesis ↓ ↑ LDL Receptors ↓ ↓ LDL Cholesterol •Therapeutic Effects •Lowers LDL cholesterol. •Useful in statin-intolerant patients. •Clinical Uses •Hypercholesterolemia. •Combination therapy with statins or ezetimibe. •Adverse Effects •Hyperuricemia. •Tendon rupture (rare). •Muscle pain. •Contraindications •Hypersensitivity. •Caution in gout.
8. OMEGA-3 FATTY ACIDS Examples:- Icosapent ethyl, Omega-3 fatty acids Mechanism of Action Omega-3 Fatty Acids ↓ ↓ Hepatic Triglyceride Synthesis ↓ ↓ VLDL Production ↓ ↓ Plasma Triglycerides •Therapeutic Effects •Reduces triglycerides. •May reduce cardiovascular risk in selected patients. •Clinical Uses •Severe hypertriglyceridemia. •Adjunct to diet and statin therapy. •Adverse Effects •Fishy aftertaste. •Dyspepsia. •Mild bleeding tendency •Contraindications •Hypersensitivity to fish-derived products. •Use cautiously with anticoagulants.